These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

706 related items for PubMed ID: 25380901

  • 1. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A, Dębska-Ślizień A, Król E, Biedunkiewicz B, Rutkowski B.
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

  • 3. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.
    Clin J Am Soc Nephrol; 2012 Mar 27; 7(3):504-12. PubMed ID: 22282478
    [Abstract] [Full Text] [Related]

  • 4. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB.
    Transplantation; 2007 May 27; 83(10):1324-9. PubMed ID: 17519781
    [Abstract] [Full Text] [Related]

  • 5. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 27; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 6. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group.
    Clin Transplant; 2002 Feb 27; 16(1):60-8. PubMed ID: 11982617
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M.
    Transplant Proc; 2009 May 27; 41(4):1175-7. PubMed ID: 19460509
    [Abstract] [Full Text] [Related]

  • 8. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK, Klinger M, Vítko Š, Glyda M, Midtvedt K, Stefoni S, Citterio F, Pietruck F, Squifflet JP, Segoloni G, Krüger B, Sperschneider H, Banas B, Bäckman L, Weber M, Carmellini M, Perner F, Claesson K, Marcinkowski W, Ostrowski M, Senatorski G, Nordström J, Salmela K.
    Transplantation; 2012 Sep 15; 94(5):492-8. PubMed ID: 22858806
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug 15; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 10. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Aug 15; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 11. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
    Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I.
    Transplantation; 1997 Dec 27; 64(12):1755-60. PubMed ID: 9422416
    [Abstract] [Full Text] [Related]

  • 12. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 27; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 13. Reduced-dose cyclosporine with mycophenolate mofetil and prednisone significantly improves the long-term glomerular filtration rate and graft survival.
    Wang R, Xu Y, Wu J, Wang Y, He Q, Chen J.
    Intern Med; 2013 Nov 27; 52(9):947-53. PubMed ID: 23648712
    [Abstract] [Full Text] [Related]

  • 14. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients.
    Cuervas-Mons V, Herrero JI, Gomez MA, González-Pinto I, Serrano T, de la Mata M, Fabregat J, Gastaca M, Bilbao I, Varo E, Sánchez-Antolín G, Rodrigo J, Espinosa MD.
    Clin Transplant; 2015 Aug 27; 29(8):667-77. PubMed ID: 25924549
    [Abstract] [Full Text] [Related]

  • 15. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reichart B, Klepetko W.
    J Thorac Cardiovasc Surg; 2003 Apr 27; 125(4):891-900. PubMed ID: 12698153
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.
    Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280
    [Abstract] [Full Text] [Related]

  • 17. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, ELITE-Symphony Study.
    N Engl J Med; 2007 Dec 20; 357(25):2562-75. PubMed ID: 18094377
    [Abstract] [Full Text] [Related]

  • 18. Diabetes mellitus after kidney transplantation in Japanese patients: The Japan Academic Consortium of Kidney Transplantation study.
    Okumi M, Unagami K, Hirai T, Shimizu T, Ishida H, Tanabe K, Japan Academic Consortium of Kidney Transplantation (JACK).
    Int J Urol; 2017 Mar 20; 24(3):197-204. PubMed ID: 27862344
    [Abstract] [Full Text] [Related]

  • 19. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.
    Jain A, Kashyap R, Dodson F, Kramer D, Hamad I, Khan A, Eghestad B, Starzl TE, Fung JJ.
    Transplantation; 2001 Sep 27; 72(6):1091-7. PubMed ID: 11579306
    [Abstract] [Full Text] [Related]

  • 20. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 27; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.